Antipsychotic (neuroleptic) of the group of substituted benzamides. It has a moderate antipsychotic as well as antidepressant effect in combination with an activating effect. The mechanism of antipsychotic action is associated with selective blockade of central dopamine D2-receptors. The sedative effect is weak, the alpha-adrenoblocking activity is low and there is almost no antimuscarinic effect. Rarely causes extrapyramidal disorders, so it belongs to the “atypical” neuroleptics. It promotes healing of ulcerative lesions of the stomach and duodenum. The information has been verified by the specialists of the site: https://pillintrip.com/medicine/eglonyl.
After volumetric administration of 100 mg of sulpiride Cmax in plasma is reached after 30 min, after oral administration – 200 mg after 4.5 hours. Bioavailability when administered orally is 25-35% and is characterized by significant individual variability.
Plasma concentration of sulpiride is proportional to the dose.
Binding to plasma proteins is not more than 40%. Sulpiride penetrates rapidly into all tissues of the body, faster – into the liver and kidneys, slower – into brain tissue (the main amount is accumulated in the pituitary gland). 0.1% of the daily dose of sulpiride is excreted with breast milk.
It is excreted unchanged by the kidneys by glomerular filtration (92%). Total clearance (usually equal to renal clearance) is 126 ml/min. T1/2 is about 7 hours.
Indications of the active substances of Eglonil®
Neurotic states with lethargy; psychosomatic disorders including, but not limited to, gastric and duodenal ulcer, UC; acute and chronic psychoses with predominant lethargy, agrammatism, abulia; acute and chronic psychoses with delirium or confusion, including schizophrenia.
Regimen of administration and dosage regimen of a specific drug depend on its form of release and other factors. The optimal dosing regimen is de
termined by the doctor. It should be strictly observed in accordance with the dosage form of the specific drug indications for use and the dosing regimen.
Orally for adults – 100-300 mg/day in 2-3 doses. If necessary, administer a daily dose of 100-800 mg/m. A daily dose of 5 mg/kg is used in children.
The maximum daily dose for oral administration in adults is 1.6 g.
CNS disorders: agita
tion, dizziness, sleep disorders, oral automatism, aphasia.
Digestive system: dry mouth, heartburn, vomiting, constipation.
: increase in blood pressure.
Endocrine system: menstrual disorders, decreased sexual activity. If prolonged use in high doses – galactorrhea, gynecomastia.
Allergic reactions: skin rash and itching.
Contraindications to use
Feochromocytoma, arterial hypertension, psychomotor agitation, hypersensitivity to sulpiride.
Administration during pregnancy and lactation
During pregnancy and lactation, use with caution and in the lowest effective doses.
Administration in renal dysfunction
In severe r
enal insufficiency, reduction of the dose or intermittent treatment is recommended.
Administration in children
Caution is necessary when used in children.
Administration in elderly patients
Caution is recommended when used in elderly patients.
Caution is used with caution in patients with parkinsonism and elderly people. In patients with severe renal insufficiency a dose reduction or intermittent treatment course is recommended.
In patients with epilepsy, a preliminary clinical and electrophysiological examination should be performed before initiation of therapy, because sulpiride lowers the threshold of seizure readiness.
In case of hyperthermia, which is one of the elements of MNS, sulpiride should be immediately discontinued.
Alcohol should be avoided during the treatment period.
Caution is used in children.
Influence on the ability to drive vehicles and mechanisms
During treatment, it is necessary to refrain from carrying out potentially dangerous activities requiring increased attention and quick psychomotor reactions.
CNS depressant drugs (opioid analgesics, hypnotics, tranquilizers, clonidine, central cough suppressants) concomitant use increases CNS depressant effect.
Concomitant use with antihypertensive agents increases antihypertensive effect and the risk of orthostatic hypotension.
Concomitant use with levodopa decreases the effectiveness of sulpiride.
There have been described cases of severe extrapyramidal reactions when concomitant use of sulpiride with lithium carbonate.
When concomitant use with fluoxetine, development of extrapyramidal symptoms and dystonia is possible.